

Annual Plan and Professional Judgment Budget FY 2023

Diane Palmieri, PhD

Deputy Director, Center for Research Strategy

The National Cancer Act of 1971

- Established the procedure for submitting NCI's annual budget, deemed the “bypass budget”



President Nixon signing the National Cancer Act of 1971

Section 407 (9) (A) – Prepare and submit, directly to the President for review and transmittal to Congress, an annual budget estimate for the National Cancer Program, after reasonable opportunity for comment (but without change) by the Secretary, the Director of the National Institutes of Health, and the National Cancer Advisory Board; and (B) receive from the President and the Office of Management and Budget directly all funds appropriated by Congress for obligation and expenditure by the National Cancer Institute.


Commemorating 50 Years



cancer.gov/news-events/nca50

NCI Annual Plan & Budget Proposal

- Professional Judgement Budget (PJB)
 - Communicates NCI's best professional judgment on the optimum funding needed to make the most rapid progress against cancer
- Annual Plan (AP)
 - Opportunity to present aspirational areas of science
 - Yearly dynamic strategic plan
 - 21st Century Cures Act calls for NIH institutes to prepare strategic plans regularly and format to a common template



At-a-Glance

New Format, Increased Interest

- FY 2022 1st completely virtual AP
 - Greater integration with cancer.gov
- OCPL had a goal to increase awareness
 - >50% increase in visits compared to the previous year
 - Over 4,400 visits linked to emails sent to grantees (n=10,904 emails delivered to grantees)
 - Over 1,900 downloads of the At-a-Glance
 - Up 70% from previous year



Scientific Priorities

- Understanding the Mechanisms of Cancer
- Preventing Cancer
- Detecting & Diagnosing Cancer
- Treating Cancer
- Advancing Public Health in Cancer
- Strengthening the Cancer Research Enterprise
 - Workforce and Infrastructure
- Understanding, Preventing, and Mitigating Cancer Disparities



Highlighted Scientific Opportunities

- FY 2022
 - Cancer Drug Resistance
 - Molecular Diagnostics for Cancer Treatment
 - Obesity & Cancer
 - Survivorship
- FY 2021
 - The Immune System and Microbiome
 - Artificial Intelligence
 - Implementation Science

FY 2023 Highlighted Scientific Opportunities

**Tumor Dynamics:
Predicting Cancer's
Trajectory Using
Tumor Atlases**

**Computer-Based Drug
Design: Advancing the
Discovery of New Cancer
Medicines**


**Precision
Prevention:
Predicting and
Intercepting Your
Cancer**

**Clinical Trials:
Bringing Cancer
Research to All Possible
Participants**





PJB Proposals – FY 2020-2023



Professional Judgement Budget Proposal for FY 2023

(DOLLARS IN MILLIONS)

FISCAL YEAR 2021 NCI BASE APPROPRIATION	\$6,365*	
TOTAL BUDGET INCREASE (Proposed Allocation)	\$1,185†	\$277 Inflation Adjustment†† \$165 Cancer Biology Research \$185 Cancer Prevention Research \$150 Cancer Detection & Diagnosis Research \$205 Cancer Treatment Research \$125 Public Health & Cancer Control Research \$78 Training & Infrastructure
FY 2023 BUDGET RECOMMENDATION	\$7,550	
FY 2023 CANCER MOONSHOT SM FUNDING	\$216	
FY 2023 TOTAL	\$7,766	


- A increase to the RPG budget for R01s
- \$50 million for the Childhood Cancer Data Initiative
- Last year of authorized Cancer Moonshot funding

* The base appropriation includes \$50 million for the 4th year of the Childhood Cancer Data Initiative, a 10-year initiative that began in FY 2020.

† The increase of \$1,185 million includes an inflation adjustment and \$908 million for additional infrastructure and cancer research in six major focus areas.

†† This adjustment includes inflation for the 2 years between FY 2021 and FY 2023.

NCI is Committed to Investigator-Initiated Research




* RPG funding levels include program evaluation and Small Business Innovation Research.

† FY 2021 reflects an estimate, and FY 2022 through FY 2025 are proposed professional judgment budget levels. Estimates beyond FY 2020 are subject to change due to unanticipated inflation rates, average cost increases, and fluctuations in application rates as the country recovers from the COVID-19 pandemic.

†† R01 paylines for FY 2022 through FY 2025 are proposed levels based on estimated funding levels included in this professional judgment budget.

Telling NCI's Story Through the Patient and the Researcher Experience





**NATIONAL
CANCER
INSTITUTE**

50 NATIONAL
CANCER
ACT **1971-2021**

cancer.gov • cancer.gov/espanol • cancer.gov/news-events/nca50